BRIEF-Neurogene And Neoleukin Announce Definitive Merger Agreement

Reuters

Jul 18, 2023

July 18 (Reuters) - Neoleukin Therapeutics Inc :

* NEUROGENE AND NEOLEUKIN ANNOUNCE DEFINITIVE MERGER AGREEMENT

* NEOLEUKIN THERAPEUTICS INC - COMBINED COMPANY IS EXPECTED TO HAVE A CASH BALANCE OF APPROXIMATELY $200 MILLION AT CLOSE

* NEOLEUKIN THERAPEUTICS INC - CASH EXPECTED TO FUND COMBINED COMPANY INTO 2H:26

* NEOLEUKIN THERAPEUTICS INC - PROPOSED MERGER TO CREATE NASDAQ-LISTED BIOTECH CO

* NEOLEUKIN THERAPEUTICS - COMBINED CO IS EXPECTED TO OPERATE UNDER NAME NEUROGENE INC. AND TRADE ON NASDAQ CAPITAL MARKET UNDER TICKER SYMBOL "NGNE"

* NEOLEUKIN THERAPEUTICS INC - COMBINED COMPANY WILL BE LED BY RACHEL MCMINN, CHIEF EXECUTIVE OFFICER OF NEUROGEN

* NEOLEUKIN THERAPEUTICS INC - PRE-MERGER NEOLEUKIN STOCKHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 16% OF COMBINED COMPANY

* NEOLEUKIN THERAPEUTICS INC - PRE-MERGER NEUROGENE STOCKHOLDERS ARE EXPECTED TO OWN ABOUT 84% OF COMBINED COMPANY

* NEOLEUKIN THERAPEUTICS INC - UPON CLOSING OF PROPOSED TRANSACTION, NEOLEUKIN THERAPEUTICS, INC., WILL BE RENAMED NEUROGENE INC

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2352829712"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2352829712\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2352829712?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-07-18 18:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2352829712","market":"us","top_or_hot":-1,"title":"BRIEF-Neurogene And Neoleukin Announce Definitive Merger Agreement","media":"Reuters","content":"<html><body><p>July 18 (Reuters) - Neoleukin Therapeutics Inc   :</p><p>   * NEUROGENE AND NEOLEUKIN ANNOUNCE DEFINITIVE MERGER AGREEMENT</p><p>   * NEOLEUKIN THERAPEUTICS INC - COMBINED COMPANY IS EXPECTED TO HAVE A CASH BALANCE OF APPROXIMATELY $200 MILLION AT CLOSE</p><p>   * NEOLEUKIN THERAPEUTICS INC - CASH EXPECTED TO FUND COMBINED COMPANY INTO 2H:26</p><p>   * NEOLEUKIN THERAPEUTICS INC - PROPOSED MERGER TO CREATE NASDAQ-LISTED BIOTECH CO</p><p>   * NEOLEUKIN THERAPEUTICS - COMBINED CO IS EXPECTED TO OPERATE UNDER NAME NEUROGENE INC. AND TRADE ON NASDAQ CAPITAL MARKET UNDER TICKER SYMBOL \"NGNE\"</p><p>   * NEOLEUKIN THERAPEUTICS INC - COMBINED COMPANY WILL BE LED BY RACHEL MCMINN,  CHIEF EXECUTIVE OFFICER OF NEUROGEN</p><p>   * NEOLEUKIN THERAPEUTICS INC - PRE-MERGER NEOLEUKIN STOCKHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 16% OF COMBINED COMPANY</p><p>   * NEOLEUKIN THERAPEUTICS INC -  PRE-MERGER NEUROGENE STOCKHOLDERS ARE EXPECTED TO OWN ABOUT 84% OF COMBINED COMPANY</p><p>   * NEOLEUKIN THERAPEUTICS INC - UPON CLOSING OF PROPOSED TRANSACTION, NEOLEUKIN THERAPEUTICS, INC., WILL BE RENAMED NEUROGENE INC</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Neurogene And Neoleukin Announce Definitive Merger Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Neurogene And Neoleukin Announce Definitive Merger Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2023-07-18 18:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>July 18 (Reuters) - Neoleukin Therapeutics Inc   :</p><p>   * NEUROGENE AND NEOLEUKIN ANNOUNCE DEFINITIVE MERGER AGREEMENT</p><p>   * NEOLEUKIN THERAPEUTICS INC - COMBINED COMPANY IS EXPECTED TO HAVE A CASH BALANCE OF APPROXIMATELY $200 MILLION AT CLOSE</p><p>   * NEOLEUKIN THERAPEUTICS INC - CASH EXPECTED TO FUND COMBINED COMPANY INTO 2H:26</p><p>   * NEOLEUKIN THERAPEUTICS INC - PROPOSED MERGER TO CREATE NASDAQ-LISTED BIOTECH CO</p><p>   * NEOLEUKIN THERAPEUTICS - COMBINED CO IS EXPECTED TO OPERATE UNDER NAME NEUROGENE INC. AND TRADE ON NASDAQ CAPITAL MARKET UNDER TICKER SYMBOL \"NGNE\"</p><p>   * NEOLEUKIN THERAPEUTICS INC - COMBINED COMPANY WILL BE LED BY RACHEL MCMINN,  CHIEF EXECUTIVE OFFICER OF NEUROGEN</p><p>   * NEOLEUKIN THERAPEUTICS INC - PRE-MERGER NEOLEUKIN STOCKHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 16% OF COMBINED COMPANY</p><p>   * NEOLEUKIN THERAPEUTICS INC -  PRE-MERGER NEUROGENE STOCKHOLDERS ARE EXPECTED TO OWN ABOUT 84% OF COMBINED COMPANY</p><p>   * NEOLEUKIN THERAPEUTICS INC - UPON CLOSING OF PROPOSED TRANSACTION, NEOLEUKIN THERAPEUTICS, INC., WILL BE RENAMED NEUROGENE INC</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FT_SY_NQ","symbol_name":"NQ100指数","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2352829712","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2352829712","pubTimestamp":1689676425,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"July 18  - Neoleukin Therapeutics Inc   :   * NEUROGENE AND NEOLEUKIN ANNOUNCE DEFINITIVE MERGER AGREEMENT   * NEOLEUKIN THERAPEUTICS INC - COMBINED COMPANY IS EXPECTED TO HAVE A CASH BALANCE OF APPROXIMATELY $200 MILLION AT CLOSE   * NEOLEUKIN THERAPEUTICS INC - CASH EXPECTED TO FUND COMBINED COMPANY INTO 2H:26   * NEOLEUKIN THERAPEUTICS INC - PROPOSED MERGER TO CREATE NASDAQ-LISTED BIOTECH CO   * NEOLEUKIN THERAPEUTICS - COMBINED CO IS EXPECTED TO OPERATE UNDER NAME NEUROGENE INC. AND TRADE ON NASDAQ CAPITAL MARKET UNDER TICKER SYMBOL \"NGNE\"   * NEOLEUKIN THERAPEUTICS INC - COMBINED COMPANY WILL BE LED BY RACHEL MCMINN,  CHIEF EXECUTIVE OFFICER OF NEUROGEN   * NEOLEUKIN THERAPEUTICS INC - PRE-MERGER NEOLEUKIN STOCKHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 16% OF COMBINED COMPANY   * NEOLEUKIN THERAPEUTICS INC -  PRE-MERGER NEUROGENE STOCKHOLDERS ARE EXPECTED TO OWN ABOUT 84% OF COMBINED COMPANY   * NEOLEUKIN THERAPEUTICS INC - UPON CLOSING OF PROPOSED TRANSACTION, NEOLEUKIN THERAPEUT","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{".IXIC":"NASDAQ Composite","PSQ":"做空纳斯达克100指数ETF-ProShares","QLD":"2倍做多纳斯达克100指数ETF-ProShares","BK4139":"生物科技","TQQQ":"纳指三倍做多ETF","QID":"两倍做空纳斯达克指数ETF-ProShares","SQQQ":"纳指三倍做空ETF","QQQ":"纳指100ETF"},"translate_title":"简介——Neurogene和Neoleukin宣布最终合并协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNQmain":0.6,"PSQ":0.6,".IXIC":0.7,"QLD":0.6,"NLTX":0.9,"TQQQ":0.6,"QID":0.6,"QQQ":0.6,"SQQQ":0.6,"NQmain":0.6},"content_text":"July 18 (Reuters) - Neoleukin Therapeutics Inc   :   * NEUROGENE AND NEOLEUKIN ANNOUNCE DEFINITIVE MERGER AGREEMENT   * NEOLEUKIN THERAPEUTICS INC - COMBINED COMPANY IS EXPECTED TO HAVE A CASH BALANCE OF APPROXIMATELY $200 MILLION AT CLOSE   * NEOLEUKIN THERAPEUTICS INC - CASH EXPECTED TO FUND COMBINED COMPANY INTO 2H:26   * NEOLEUKIN THERAPEUTICS INC - PROPOSED MERGER TO CREATE NASDAQ-LISTED BIOTECH CO   * NEOLEUKIN THERAPEUTICS - COMBINED CO IS EXPECTED TO OPERATE UNDER NAME NEUROGENE INC. AND TRADE ON NASDAQ CAPITAL MARKET UNDER TICKER SYMBOL \"NGNE\"   * NEOLEUKIN THERAPEUTICS INC - COMBINED COMPANY WILL BE LED BY RACHEL MCMINN,  CHIEF EXECUTIVE OFFICER OF NEUROGEN   * NEOLEUKIN THERAPEUTICS INC - PRE-MERGER NEOLEUKIN STOCKHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 16% OF COMBINED COMPANY   * NEOLEUKIN THERAPEUTICS INC -  PRE-MERGER NEUROGENE STOCKHOLDERS ARE EXPECTED TO OWN ABOUT 84% OF COMBINED COMPANY   * NEOLEUKIN THERAPEUTICS INC - UPON CLOSING OF PROPOSED TRANSACTION, NEOLEUKIN THERAPEUTICS, INC., WILL BE RENAMED NEUROGENE INCSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}